Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- As Off-Year Re-Pricing Looms, JPMA Chief Prods Govt to Minimize Product Coverage
January 7, 2020
- Generic Use Rate at 76.9% in July-September: JGA
December 27, 2019
- Boehringer’s Thorsten Poehl Named as New EFPIA Japan Chief
December 24, 2019
- Industry Leaders Issue Statements on FY2020 Reform Package; Improved PMP Criteria Given Certain Credit
December 23, 2019
- With PMD Law Amended, Japan Pharma Industry Revs Up Work for Electronic Distribution of Prescribing Info
December 5, 2019
- Generic Association to Present Policy Proposal for Govt’s 2020 Honebuto Policy
November 20, 2019
- RIKEN Develops Supercomputer for Molecular Dynamics Simulation, Will Be Made Available to Drug Makers for Drug Discovery Use
November 19, 2019
- JPWA Compares Traceability Regulations to Prevent Distribution of Counterfeit Drugs in Japan, US, EU
November 13, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Obituary: Harrison Cook, Eli Lilly
October 15, 2019
- Japan Pharmacist Group Taps Ex-Bureaucrat Isobe for Director Post
October 11, 2019
- Patients Want Access to Innovative Drugs Even If Expensive: PhRMA Survey
October 7, 2019
- PhRMA Chair Urges Japan to Rectify PMP Criteria, Narrow Definition of Innovation
October 4, 2019
- Japan Doctors’ Group to Issue Statement to Push for HPV Vaccines by FY2019-End
October 3, 2019
- Generic Industry Pondering Specific Proposal to Address Unreasonable Price Rises
October 2, 2019
- Generic Association Focuses on Pre-symptomatic/Preventive Care and Overseas Expansion in “Post-80% Era”
October 2, 2019
- Generic Use Rate at 75.8% in April-June: JGA
September 27, 2019
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
- EFPIA Japan Stresses Safety First and Need for Doctors’ Support on Delisting of OTC-Like Drugs, Notes Good Examples Overseas
September 25, 2019
- FPMAJ Sets Up New Taskforce to Promote Access to Japanese Drugs in Asia
September 24, 2019
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…